Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

BACKGROUND: Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) and agonistic antibodies to death receptor 4 and 5 are promising candidates for cancer therapy due to their ability to induce apoptosis selectively in a variety of human cancer cells, while demonstrating little cytotoxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, David J, Parsons, Christine E, Han, Haiyong, Jayaraman, Arul, Rege, Kaushal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223153/
https://www.ncbi.nlm.nih.gov/pubmed/22044796
http://dx.doi.org/10.1186/1471-2407-11-470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223153/
https://www.ncbi.nlm.nih.gov/pubmed/22044796
http://dx.doi.org/10.1186/1471-2407-11-470

Ejemplares similares